Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months followup

Iddo Z. Ben-Dov, Yonatan Oster, Keren Tzukert, Talia Alster, Raneem Bader, Ruth Israeli, Haya Asayag, Michal Aharon, Ido Burstein, Hadas Pri-Chen, Ashraf Imam, Roy Abel, Irit Mor-Yosef Levi, Abed Khalaileh, Esther Oiknine-Djian, Aharon Bloch, Dana G. Wolf, Michal Dranitzki Elhalel
doi: https://doi.org/10.1101/2021.06.12.21258813

Data Availability

Data is not available

Back to top
Posted July 17, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months followup
Iddo Z. Ben-Dov, Yonatan Oster, Keren Tzukert, Talia Alster, Raneem Bader, Ruth Israeli, Haya Asayag, Michal Aharon, Ido Burstein, Hadas Pri-Chen, Ashraf Imam, Roy Abel, Irit Mor-Yosef Levi, Abed Khalaileh, Esther Oiknine-Djian, Aharon Bloch, Dana G. Wolf, Michal Dranitzki Elhalel
medRxiv 2021.06.12.21258813; doi: https://doi.org/10.1101/2021.06.12.21258813
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area